论文部分内容阅读
目的:探究乌司他丁联合阿托莫兰对感染性休克患者血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和降钙素原(PCT)水平的影响。方法:选择2013年6月~2015年12月期间我院收治感染性休克患者79例为研究对象;采用随机数字法将其分为观察组(39例)和对照组(40例),观察组患者给予乌司他丁联合阿托莫兰治疗,对照组给予常规抗感染治疗;观察并比较两组患者治疗前后IL-6、TNFα和PCT水平,比较两组患者药物不良反应、多器官功能障碍综合征(MODS)发生率及病死率。结果:治疗前两组患者间IL-6、TNF-α及PCT水平均无差异(P<0.05);治疗后两组患者IL-6、TNF-α及PCT均显著下降,且观察组IL-6、TNF-α及PCT水平低于对照组(P<0.05);治疗过程中两组患者药物不良反应发生率无差异(P>0.05);治疗后观察组MODS及死亡发生率均低于对照组(P<0.05)。结论:乌司他丁联合阿托莫兰能够改善对感染性休克患者炎症反应,降低机体IL-6、TNF-α及PCT水平,降低MODS发生率及病死率,在临床治疗感染性休克具有重要价值。
Objective: To investigate the effects of ulinastatin combined with atorolan on the levels of serum interleukin-6, tumor necrosis factor-α (TNF-α) and procalcitonin (PCT) in septic shock patients . Methods: Seventy-nine patients with septic shock admitted to our hospital from June 2013 to December 2015 were selected as study objects. The patients were divided into observation group (39 cases) and control group (40 cases) by random number method. Observation group The patients were treated with ulinastatin combined with atorolan and the control group with conventional anti-infective therapy. The levels of IL-6, TNFα and PCT before and after treatment were observed and compared between the two groups. The adverse drug reaction, multiple organ dysfunction Syndrome (MODS) incidence and mortality. Results: The levels of IL-6, TNF-α and PCT in the two groups before treatment were not significantly different (P <0.05). After treatment, the levels of IL-6, TNF- 6, TNF-αand PCT levels were lower than those in the control group (P <0.05). There was no difference in the incidence of ADRs between the two groups during the course of treatment (P> 0.05). The incidences of MODS and death in the observation group were lower than those in the control group Group (P <0.05). Conclusion: Ulinastatin combined with atorolamine can improve the inflammatory response in septic shock patients, reduce the body’s IL-6, TNF-α and PCT levels, reduce the incidence of MODS and mortality, which is important in the treatment of septic shock value.